spacer
home > ebr > summer 2002 > a case for alternative financing in biomedical companies industry dynamics
PUBLICATIONS
European Biopharmaceutical Review

A Case for Alternative Financing in Biomedical Companies INDUSTRY DYNAMICS

The biomedical sector is gripped by the imminent threat, or promise, of consolidation. Many company founders and investors may lose their investments and the efforts of the last five years without a flexible response to the strains imposed on their current business plans. For some, the only alternative will be to restructure their business strategy and to adjust to the needs of the changing market conditions.In such challenging times, seeking an alternative approach to the traditional financing of biomedical businesses may be prudent. This article aims to review some of the better known choices for companies at each stage of development, and to introduce a new alternative approach which may be of vital interest in the future, particularly for those at a later stage of development.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Martin Austin, Director of European Operations, Paul Royalty Funds at Paul Capital Partners

Martin Austin is Director of European Operations at Paul Royalty Funds. Martin joined Paul Capital Partners in 2000 to lead the European activities for the Royalty Acquisition Fund in sourcing and due diligence. In 1988 he co-founded Machine Intelligence Technologies in the UK following over 25 years in the pharmaceutical industry with G. D. Searle and Synthйlabo, and as a Consultant with Marketing Improvements Ltd.
He then went on to found MHIG Ltd - a UK/German joint venture market research consultancy. In 1996 he joined F-Hoffmann-La Roche in Basel, Switzerland, becoming global Head of Business Development for Pharmaceuticals. Martin has an Advanced Certificate in Education from Reading University and a BA from the UK Open University.

spacer
Martin Austin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Irelandís premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement